Set2 Inhibitors

Set2 inhibitors operate through multiple approaches to modulate the protein's activity, predominantly by disrupting either its interactions with other proteins or its role in chromatin modification. For example, Anacardic Acid inhibits histone acetyltransferases, which indirectly influences the Set2-dependent histone methylation process. CBP/p300 bromodomain inhibitors like SGC-CBP30 work by the interaction between Set2 and CBP/p300. Such disruption is crucial as this interaction often precedes or accompanies Set2's role in chromatin modification. In contrast, MEK inhibitors like Compound 2i directly modulate intracellular signaling cascades, such as the MAPK pathway, which can influence the phosphorylation state of proteins that interact with Set2. This leads to alterations in Set2-dependent pathways involving those phosphorylated transcription factors.

Another class of Set2 inhibitors are those that act through histone modification, particularly EZH2 inhibitors like UNC1999 and GSK126. These chemicals act by inhibiting the methylation of H3K27, an event that can create an altered chromatin state affecting Set2-mediated H3K36 methylation. In a similar vein, HDAC inhibitors like Trichostatin A and SAHA modify the chromatin landscape by affecting histone deacetylation, impacting Set2's access to its histone targets. These inhibitors effectively disrupt or modulate the cellular functions of Set2 through their precise action on these biochemical pathways and protein interactions.